Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Graft vs Host Disease Clinical Trial

Official title:

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05531786
• Other study ID #: 10000643
• Secondary ID: 000643-C
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 6, 2023
• Est. completion date: November 2, 2024

Study information

• Verified date: June 3, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Rania S Hishmeh, R.N.
• Phone: (240) 858-3166
• Email: rania.hishmeh[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant. cGVHD can affect multiple organs and increase risk of disability and death. New treatments are needed to treat cGVHD after stem cell transplant.

Objective:

To test a drug (pacritinib) in people with moderate or severe cGVHD that has not responded to previous treatment.

Eligibility:

People aged 18 years and older with moderate or severe cGVHD that has not responded to 2 or more lines of previous treatment.

Design:

Participants will be screened. They will have blood and urine tests. They will have tests of their heart and lung function. They may also have a CT scan. Some may have other specialized tests.

Participants will take the study drug at home every day. Pacritinib is a capsule taken by mouth. The study doctor will determine the dosage and schedule.

Participants will keep a medication diary. They will record the date and time of each drug dose and any missed doses.

Participants will visit the clinic every 2 weeks for the first 4 months. Then they will visit the clinic once every 4 weeks. They will have blood and urine tests. During some visits, other screening tests will be repeated, and participants will fill out questionnaires about their quality of life. Photographs may be taken of skin rashes and joints affected by cGVHD.

Participants will give saliva samples. Optional biopsies may be taken of the skin and mouth.

Participants will take pacritinib for 6 to 12 months if no side effects develop. Follow-up visits will continue for up to 2 years.

...

Description:

Background:

• Chronic GVHD (cGVHD) is a multi-organ disorder characterized by immune dysregulation, impaired organ function, and decreased survival for hematopoietic stem cell transplantation (HSCT) patients.

• The JAK-STAT pathway plays an important role in immune cell development and function, including antigen presenting cells, B- and T-cells, and its activation leads to a cascade promoting a proinflammatory cytokine milieu.

• Pacritinib is a JAK2/IRAK1/CSF1R/FLT3 inhibitor, with an established safety and efficacy profile in the treatment of myeloproliferative neoplasms (myelofibrosis) and of acute GVHD.

• Pacritinib s immunomodulatory effects suggest therapeutic benefit for cGVHD, without abrogating the graft-versus-leukemia effect after HSCT.

Objectives:

• Phase I: to determine the safety of pacritinib in participants with refractory cGVHD

• Phase II: to determine the efficacy of pacritinib in participants with refractory cGVHD

Eligibility:

• Moderate or severe cGVHD (after allogeneic hematopoietic stem cell transplantation) diagnosed and staged per NIH criteria.

• cGVHD that did not respond to at least two prior lines of systemic therapy.

• Age greater than or equal to18 years.

• If participant is taking systemic therapy for cGVHD at the time of enrollment, they must be on stable or tapering doses in the preceding 4 weeks.

• Participants must have adequate organ and marrow function.

Design:

• This Phase I/II study will use a modified 3+3 dose-escalation design, with two planned dose levels of pacritinib, followed by a small efficacy evaluation in a randomized phase II design.

• Pacritinib will be given taken orally once or twice daily (based on dose level) on days 1- 28 of a 28-day cycle.

• Pacritinib treatment will continue for up to 12 months. cGVHD response will be evaluated at 6 weeks, and 3, 6, 9 and 12 months from the start of pacritinib. All participants will be followed through 2 years post-initiation of pacritinib.

• Total maximum number of participants to be enrolled is 30, with accrual ceiling set at 50 participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 2, 2024
• Est. primary completion date: November 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

-INCLUSION CRITERIA:

1. Moderate or severe cGVHD (after allogeneic hematopoietic stem cell transplantation) diagnosed and staged per NIH criteria

2. cGVHD that did not respond to greater than or equal to 2 lines of prior systemic therapy.

Disease that has failed prior systemic therapy will be defined as follows:

a) For prior corticosteroid-containing regimens, disease that:

i) recurs after achievement of a CR, or

ii) progresses after achievement of a PR, or

iii) progresses after at least 1 week of prednisone equivalent of 1 mg/kg/day, or

iv) is stable and persistent after at least 4 weeks of a prednisone equivalent of 0.5 mg/kg/day

OR,

b) For other systemic therapies, disease that:

i) recurs after achievement of CR, or

ii) progresses after achievement of a PR, or

iii) is stable and persistent despite 4 weeks of therapeutic dosing of systemic therapy

3. Karnofsky performance score greater than or equal to 60%

4. Age >=18 years.

5. If participant is taking systemic therapy for cGVHD at the time of enrollment, they must be on a stable or tapering dose in the preceding 4 weeks.

6. Participants must have adequate organ and marrow function as defined below:

• absolute neutrophil count >=1,000/mcL

• platelets >=50,000/mcL

• total bilirubin <=1.5 X institutional upper limit of normal

OR

<=3 X institutional upper limit of normal in participants with Gilbert s syndrome

• AST(SGOT)/ALT(SGPT) <=3 X institutional upper limit of normal

• creatinine clearance >=50 mL/min/1.73 m^2 per Cockroft-Gault

7. Primary malignancy for which the participant received transplant has been in complete clinical remission and stable for 3 months prior to enrollment on study.

8. Women of child-bearing potential and men who are sexually active must agree to use one (1) highly effective (e.g., intrauterine device [IUD], hormonal, surgical) or two (2)effective forms of contraception (e.g., barrier method) at study entry, for the duration of study treatment, and for at least 30 days after last study drug exposure.

9. Ability of participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

1. Acute GVHD that is active as defined by exhibiting current signs or symptoms of disease without any chronic GVHD (classic and late-acute GVHD per NIH consensus criteria); participants with a clinical presentation consistent with overlapping acute GVHD with concurrent chronic GVHD will be eligible

2. Treatment with ruxolitinib, or ibrutinib within the for <= 14 days prior to treatment initiation.

3. Active HIV-1 (detectable HIV viral load), or Hepatitis B (HBV) and/or Hepatitis C (HCV) infection (positive HBV or HCV viral load in the setting of positive HBV core antibody or surface antibody or HCV antibody).

4. Participants with the following cardiac conditions at screening:

• symptomatic congestive heart failure

• unstable angina pectoris

• uncontrolled cardiac dysrhythmias

• QTc(F) prolongation >450 ms or other factors that increase the risk for QT prolongation (i.e., heart failure, or a history of long QT interval syndrome).

5. Left ventricular ejection fraction <= 50% by transthoracic echocardiogram (TTE) at screening.

6. Participants with poor pulmonary function as defined by a forced expiratory volume in the first second (FEV1) <= 39% calculated using the USA-ITS-NIH equation.

7. Participants with evidence of ongoing hemorrhage, active signs/symptoms of bleeding, or history of severe bleeding complications in the one year prior to enrollment.

8. Concurrent treatment with any other investigational agents.

9. Concurrent use of strong CYP3A4 inducers or inhibitors, must stop 2 weeks prior study drug initiation.

10. Known hypersensitivity to JAK inhibitors.

11. Participants who are unwilling to accept blood transfusions.

12. Pregnancy or breastfeeding.

13. Participants with any active, uncontrolled viral, bacterial, or fungal infection are excluded.

14. Other malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix or breast which requires active treatment.

15. Uncontrolled intercurrent illness evaluated by history, physical exam and chemistries or situation that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Bronchiolitis Obliterans Syndrome
• Graft vs Host Disease

Intervention

Drug:
• Pacritinib
Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Safety of pacritinib in refractory cGVHD.	grades and types of toxicity reported at each dose level. The overall estimate of the fraction of patients who have a DLT at the MTD will be reported.	60 days
Primary	Phase II: Overall response rate (ORR)	the fraction with clinical responses reported separately by arm, with a separate 95% confidence interval for each cohort.	6 months
Secondary	Phase I: Pharmacokinetics (PK)	The secondary endpoint for PK properties includes measures such as AUC, half-life, and steady-state concentration.	every 3 months through up to 12 months of treatment
Secondary	Phase 2: Safety	Toxicities identified from day 1 of study drug, collected every 2 weeks through cycle 4, then per cycle through 30 days after the study drug administration. AEs are reported by type and grade	every 3 months through up to 12 months of treatment
Secondary	Phase 2: Clinical outcomes	Rate of reduction and/or discontinuation of immunosuppressive therapy; response by organ system; time to response; duration of best response; and, failure-free survival	every 3 months through up to 12 months of treatment

External Links

•   NIH Clinical Center Detailed Web Page